Qingdao Baiyang Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without any false records, misleading statements, or significant omissions.
Recently, to meet the funding needs for the business development of its subsidiary, the Company has provided a joint liability guarantee for the working capital loan of its wholly-owned subsidiary, Beijing Baiyang Zhihhe Medical Achievement Transformation Service Co., Ltd. (hereinafter referred to as "Baiyang Zhihhe"). The specific situation is as follows:
1. Overview of the Guarantee
The Company held the 31st meeting of the third Board of Directors on April 22, 2025, and the 2024 Annual General Meeting of Shareholders on May 14, 2025, where it reviewed and approved the proposal on the expected external guarantee limit for 2025, agreeing to provide a guarantee limit of no more than RMB 200 million for Baiyang Zhihhe, valid for 12 months from the date of the resolution passed at the 2024 Annual General Meeting of Shareholders. For details, please refer to the relevant announcements disclosed by the Company on the Giant Tide Information Network (www.cninfo.com.cn).